Three months ago, Schneider National delivered the kind of quarter trucking investors had been waiting years to see. Adjusted earnings more than doubled from the first quarter, truckload margins hit their best level since 2023, and management raised its full-year outlook at both ends. The stock has since fallen about 13% while the S&P 500 gained nearly 4%. When the company reports third-quarter results after the close on October 29, the question is whether the market's skepticism or the company's upcycle narrative is closer to the truth.
SPS Commerce heads into its third-quarter report with a cleaner story than it has told in a year and a stock that has already priced in a good deal of that clarity. The sale of its Amazon third-party revenue recovery business, which closed at the end of June, removed the drag that had clouded three straight conference calls. What remains is a first-party supplier network that management says is growing at a high-single-digit pace with expanding margins. The report due after the close on October 29 is the first full quarter without that business, making it the first clean read on whether the core really is as healthy as management described.
SPX Technologies heads into its third-quarter report with an unusual disconnect. Management has raised its full-year outlook twice in a row, lifted its data center revenue target to roughly $430 million and nearly doubled its view of eventual data center capacity. Yet the stock has fallen about 21% since the last report while the S&P 500 gained nearly 4%. The results due after the close on October 29 need to show whether the market is anticipating a problem the company has not yet disclosed, or simply discounting a story that is still running ahead of plan.
Strattec Security heads into its fiscal first-quarter report with an unusual split in expectations. Wall Street sees sales holding nearly steady while profits fall sharply. That gap tells the story of a company that just finished a record year, then warned that the year ahead would be harder. Thursday's results will be the first real evidence of how much harder.
Starz enters its third-quarter report in an unusual position: management has already told investors this will be the weakest quarter of the year for profitability, yet the stock's direction likely hinges on whether the streaming turnaround that emerged last quarter keeps building underneath that trough. On the second-quarter call, the company said adjusted OIBDA would bottom in the mid-$30 million range as programming amortization bunches up, down sharply from the $60 million it just delivered. That makes the headline profit number less of a surprise risk than usual. The real test is whether the operating story holds while margins dip.
Supernus Pharmaceuticals heads into its third-quarter report with an unusual problem: its biggest story is no longer its own quarter. Since announcing an all-stock merger of equals with Indivior, the company has asked investors to value it as part of a pro forma CNS business with roughly $2.2 billion in trailing revenue and EBITDA margins near 41%, more than double Supernus's standalone margin of about 18%. That vision only holds if the Supernus half keeps delivering. Thursday's results, due after the close on October 29, are the cleanest look at whether the asset Supernus is contributing to the deal is still growing the way management said it was.
Three months ago Stryker looked like a company that had put its worst quarter behind it. Organic growth snapped back to 9% after a cyber incident crushed first-quarter results, margins rebounded, and management resumed share buybacks for the first time in roughly six years. The stock has since fallen about 10% while the S&P 500 gained nearly 4%, which means the third-quarter report, due after the close on October 29, arrives with the market openly doubting the recovery story management told in July.
The Bancorp walks into its third-quarter report with an odd disconnect. Three months ago management finally lifted its full-year outlook after three straight quarters of simply reaffirming it, pointed to accelerating fintech volumes and cleaner credit, and unveiled fresh growth catalysts. The market has responded by knocking the stock down about 23% while the S&P 500 gained nearly 4%. Thursday's release, due after the close on October 29, has to show whether that gap reflects a business losing steam or a market that has stopped believing the story.
TFI International delivered one of the cleaner turnarounds in freight last quarter, and the market has spent the months since acting as if it never happened. Adjusted earnings of $1.85 a share blew past management's $1.50 to $1.60 guide, consolidated operating margin roughly doubled from the first quarter to 11.6%, and the truckload unit posted a 660 basis point swing in its operating ratio in a single quarter. Yet the stock has fallen about 20% since that report, trailing the S&P 500 by nearly 25 percentage points. The third-quarter release after the close on October 29 will show whether that selloff was a sensible discount for a fragile recovery or an overreaction to a story that is still working.
Twilio heads into its third-quarter report carrying the kind of momentum that makes a company dangerous to bet against and difficult to impress. Last quarter brought a sweeping guidance raise, a fifth straight quarter of accelerating gross profit growth, and a clear shift in how management talks about AI. Executives no longer describe it as early experimentation. They now call it a durable multi-year tailwind. Management also warned that the outsized beats of the first half should not be treated as the new normal, while the stock has climbed well ahead of the market. The question for October 29 is whether Twilio can keep the acceleration story alive even if it delivers only a conventional beat.
Vale heads into its third-quarter report with a split personality. Three months ago, management sounded more confident than it had in some time, cutting cost guidance for copper and nickel, nudging production midpoints higher, accelerating the Bacaba copper project and approving both a $1.7 billion dividend and a fresh buyback of up to 100 million shares. The stock has responded by falling 15.3% since that report, trailing the S&P 500 by more than 20 percentage points. That gap between an improving base metals story and a deteriorating share price is the central tension when Vale reports after the close on October 29.
Veralto has spent 2026 steadily raising the bar on itself, and now Wall Street has jumped over it. After lifting its full-year earnings outlook twice, management guided third-quarter adjusted earnings to $1.06 to $1.09 per share. Analysts have since pushed consensus to $1.10, a penny above the top of that range. That gap is small, but the message is clear. The Street now expects the water and product-quality company to beat its own guidance, and to do it without the one-time help that flattered last quarter.
World Kinect enters its third-quarter report in an unusual position: management has spent months raising its outlook while warning everyone not to get used to it. The second quarter delivered record gross profit of $350 million and record adjusted earnings of $1.29 a share. Executives framed much of that windfall as a product of Middle East volatility and elevated fuel prices, and they told investors to expect a more measured second half. The October 29 release, due after the close, will show how quickly that tailwind is fading and how much of the improvement is structural.
W&T Offshore heads into its third-quarter report with a split personality. The stock has been trading on the possibility of a large legal windfall and a share repurchase, while the quarter itself is expected to show a loss and a sharp sequential drop in revenue. The question for this release is whether the steady, cost-focused business underneath the litigation story is generating enough cash to make management's more confident tone credible.
Weyerhaeuser heads into its third-quarter report with an awkward disconnect. Three months ago, management described a wood products business climbing steadily out of a deep trough, nudged up its land solutions outlook and sounded more confident about pricing. Since then the stock has fallen 21.5%, trailing the S&P 500 by more than 25 percentage points. Either the market sees cracks the company has not yet acknowledged, or shares have been marked down past what the operating trends justify. Thursday's numbers, due after the close on October 29, should help settle which.
Invesco Mortgage Capital spent the second quarter doing what mortgage REITs do when they believe the opportunity is attractive: issuing stock and buying more bonds. The portfolio swelled to $8.2 billion, up more than 12% in a single quarter and roughly 44% from a year earlier. The market's verdict since then has been harsh. Shares have fallen nearly 27% since the last report while the S&P 500 gained about 4%, and the stock now sits at $5.42, well below its 200-day moving average of $7.78 and just a few percent above its post-earnings low of $5.22. The third-quarter report, due after the close on October 29, will show whether that expansion was well timed or whether the company scaled up just as the rate backdrop turned against it.
OFS Capital enters its September-quarter report with a split personality. Its balance sheet has rarely looked sturdier, yet its core earning power has rarely looked weaker. Last quarter management declared the deleveraging phase finished and said the priority now is putting capital back to work. Thursday's release, due after the close on October 29, is the first real chance to see whether that shift from defense to offense shows up in the income statement or remains a talking point.
OSI Systems heads into its fiscal first-quarter report with a credibility question layered on top of a very good balance sheet story. Last quarter the company posted record margins, record cash flow and a record backlog near $1.9 billion, yet it still missed its own full-year revenue range after raising guidance twice, blaming roughly $50 million of Middle East security deliveries that slipped past year-end. Management framed that shortfall as a timing issue. The September quarter is the first real chance to see whether those shipments actually show up.
BridgeBio heads into its third-quarter report with a split personality. The operating story has rarely looked better: Atruvi keeps adding revenue at a steady clip, three late-stage drugs are under FDA review, and a $1 billion financing has pushed cash to roughly $1.7 billion. Yet the stock has fallen 22.2% since the last report while the S&P 500 was essentially flat. The quarter after the market closes on October 29 is a test of which version of BridgeBio the market believes.
Stoke Therapeutics heads into its third-quarter report with the hard work of enrolling its pivotal Dravet syndrome trial behind it. The question now is whether the regulatory groundwork laid out last quarter is holding together. The company is still pre-commercial, so the income statement will tell investors relatively little. What matters is whether management can show that the planned FDA pre-NDA meeting produced clarity on how the Phase 3 Emperor study will be judged. The market has grown impatient waiting for that answer.
Credit Acceptance enters its third-quarter report with something it has not had in a long while: a growth story. After four straight calls in which unit volume declines narrowed, from a 16.5% drop a year earlier to just 1% last quarter, monthly volume turned positive in June and jumped more than 20% in July. The stock has not celebrated. Shares have fallen 8.9% since the last report while the S&P 500 was essentially flat, which tells you the market is treating the rebound as a promise rather than a fact. When the company reports after the close on October 29, the question is whether the summer surge was the start of a trend or mostly the product of an easy comparison.
Cavco Industries enters its fiscal second-quarter report with a split personality. Demand looks better than at any point in the past year, with record shipments and an order book that swelled by half in a single quarter. Yet the stock has drifted lower since that upbeat report, because each extra home has been earning less. The release after the close on October 29 should show whether volume can begin to outrun the cost pressures that have been eroding profit.
Rocket Companies heads into its third-quarter report with a split personality. On its last call, management described what amounted to its best operating stretch in years: record purchase and refinance market share, the most profitable quarter in four years, and an expanded cost-savings target from the Mr. Cooper integration. In the same breath, it warned that the mortgage market would shrink sequentially for the first time since 2022 and guided revenue lower. The stock has sided firmly with the second half of that story, and the October 29 report, due after the close, will show whether execution can keep earnings moving up while the market moves down.
Civeo heads into its third-quarter report with a reaffirmed full-year outlook and a stock that suggests the market has stopped believing in it. Since the last report, shares have fallen about 12% while the S&P 500 gained nearly 4%. They now sit at $27.25, just above the post-earnings low of $27.13 and well below the 200-day moving average near $30.86. The question for October 29 is whether the company can show that its North American growth story is slipping on timing rather than coming apart.
Standex International closed its fiscal year by telling investors its long-promised inflection point had arrived, backed by accelerating organic growth, a record order haul and a newly quantified roadmap for its grid business. The stock has since fallen about 21%, trailing the S&P 500 by roughly 23 percentage points. That gap between an increasingly confident management team and an increasingly skeptical market is what makes the fiscal first-quarter report, due after the close on October 29, worth close attention.
AbbVie heads into its third-quarter report with an unusual tension. Its revenue outlook has climbed every quarter this year, yet its earnings-per-share forecast keeps moving the other way. Analysts have quietly sided with the business over the guidance. That makes this report less about whether the core franchise is healthy and more about whether it is healthy enough to absorb the cost of the Apogee deal.
AstraZeneca heads into its third-quarter report with a story that has two halves pulling in opposite directions. The newer franchises in oncology and rare disease keep doing the heavy lifting, while the loss of exclusivity on Farxiga is now fully visible and the failure of Wynua in a large cardiomyopathy trial removed one of the company's most heavily promoted growth drivers. The October 30 release, due before the opening bell, is the first full quarter where investors can judge whether the remaining engines are strong enough to absorb both blows without strain.
BP heads into its third-quarter report with an unusual equation for investors to solve. Wall Street expects revenue to fall from the prior quarter while profit per share rises meaningfully. That combination only works if margins widen, and with the stock trading near its highest level since the last report, the market appears to be betting that they will.
Banco Santander Chile heads into its third-quarter report with an awkward setup. The company just delivered $0.90 a share, its strongest result in recent memory, yet the Street is penciling in only $0.65 for the September quarter. That figure would still mark solid growth from a year ago. The question is whether last quarter's surge was a new baseline or a peak that is already fading. The stock appears to be voting for the second answer.
BrightSpring Health Services heads into its third-quarter report with an unusual disconnect. Management has raised its full-year outlook three times in a row, lifted its cash flow forecast, won credit upgrades and cut its borrowing costs, yet the stock has fallen about 10% since the last report while the S&P 500 gained nearly 4%. The question for this release is whether the operating story is still accelerating or whether the market is quietly betting that the best of the year is already behind it.
Cboe Global Markets heads into its third-quarter report with the stock pressing against its post-earnings high and a management team that has spent the past year raising the bar on itself. Organic revenue guidance has climbed from mid-single digits to mid-to-high teens in three steps, margins hit a record last quarter, and the company has shifted from pruning its portfolio to launching new products. The October 30 release, due before the open, is the first real test of whether that offense-minded story still has room to run.
Cameco heads into its third-quarter report with an awkward mismatch between what the Street is projecting and how the stock is behaving. Analysts expect earnings to more than quadruple from a year ago, yet the shares have fallen 9.5% since the last report while the S&P 500 gained 3.8%. That 13-point gap suggests the market is skeptical that the uranium producer can deliver on a growth story that looks impressive on paper.
Church & Dwight enters its third-quarter report with an unusual problem for a consumer staples company: management may have been too modest. After posting organic growth of 5% in the first quarter and 5.8% in the second, both well above its own roughly 3% outlooks, the company guided to only about 3% organic growth for the third quarter. The question on October 30 is whether that guide was prudence or a real slowdown, and the answer will shape how much credit the stock deserves after a strong run.
Colgate-Palmolive heads into its third-quarter report with an unusual gap between what management says and what Wall Street believes. Three months ago the company raised its full-year earnings outlook to roughly $3.88 per share, near the top of its prior $3.73 to $3.91 range, and lifted its gross margin view to roughly flat after cutting it just one quarter earlier. Analysts have not fully bought in. The Street's full-year estimate sits at $3.81, noticeably below management's target, which suggests skepticism that the second half can absorb what the company itself called peak raw material and tariff pressure. Some of that gap may reflect differences in how one-time items are treated, but the direction of the doubt is clear.
Canadian National heads into its third-quarter report with an unusual gap between what management has promised and what Wall Street believes. The railroad raised its 2026 earnings outlook to a range of roughly $5.68 to $5.95 per share, up from $5.40 to $5.69. Yet the full-year consensus of $5.67 still sits just below the bottom of that new range. Analysts have not fully bought the upgrade, and the stock has lagged since the last report. This quarter is CN's chance to show the raise was earned.
Capri Holdings heads into its fiscal second-quarter report with a peculiar setup: management has already told the Street that sales will shrink, and the real question is whether everything else in the story can hold together while they do. Last quarter the company beat on revenue, margin and earnings, then cut its full-year sales outlook anyway, preserving its profit target only by trimming expenses. This report is the first chance to see whether that trade-off was prudent housekeeping or an early sign that the Michael Kors recovery keeps slipping further out.
Chevron's last quarter was the kind oil bulls dream about: adjusted earnings of $6.06 a share, more than four times the prior quarter, alongside record U.S. output, cost targets reached early and a 20-year power deal with Microsoft. The market has already rewarded that story generously. So the third-quarter report, due before the open on October 30, raises a harder question. Was the second quarter a durable new baseline built on volume and efficiency, or a peak propped up by unusually rich refining margins?
Dominion Energy heads into its third-quarter report with a peculiar disconnect. The regulated business underneath has rarely looked stronger, with record peak demand in Virginia and a data-center pipeline that keeps swelling. Yet the stock has slid about 10% since the last report, trailing the S&P 500 by roughly 14 percentage points. Investors appear to be discounting the company's growth story because of two distractions: a six-month slip at the Coastal Virginia Offshore Wind project and the regulatory journey of the pending combination with NextEra Energy. This report is a chance to show that the core earnings engine is running on schedule regardless.
Exelon heads into its third-quarter report with a reaffirmed plan, a beaten-down stock and a calendar full of known headwinds. Wall Street is bracing for a year-over-year earnings decline. The real question is whether a July employee strike at PECO, a punishing storm season and the unresolved Pennsylvania rate situation are temporary blemishes or the start of slippage in a growth story management has defended for four straight quarters.
Forum Energy Technologies heads into its third-quarter report with something oilfield equipment makers rarely enjoy: momentum that management attributes to its own execution rather than a rising tide. Last quarter the company beat the top of its guidance across revenue, EBITDA and net income, raised its full-year outlook for the third straight time, and argued that the gains came from market-share wins rather than a better market. The stock has since climbed about 41%. That leaves this report with a narrower job and a higher bar. It no longer has to show that the turnaround is real. It has to show that last quarter's margin surprise was not a one-off.
Federal Realty Investment Trust heads into its third-quarter report with an odd disconnect. Management has raised its full-year outlook on four consecutive calls, just posted the biggest leasing quarter in company history and sounded more confident than at any point in the past year. Yet the shares have fallen 16.2% since the last report while the S&P 500 gained 3.8%. The October 30 release, due before the open, has to show that the operating story is still intact during a quarter management itself flagged as the soft spot of 2026.
General Dynamics heads into its third-quarter report with an awkward disconnect. Three months ago, management delivered its second straight guidance raise, a record backlog and some of the strongest business jet orders in years. Since then, the stock has fallen 13.6% while the S&P 500 gained 4.5%. The market seems to doubt that the momentum can hold. The report before Thursday's open is a chance to show whether that skepticism is misplaced or early.
Three months ago Gates Industrial told investors that the long-awaited industrial upturn had finally arrived. Management reported record quarterly sales, raised its full-year outlook for the first time in the cycle, and said orders were still rising into July. The market has not bought it. Shares have slipped about 1% since that report while the S&P 500 gained nearly 4%, and trader sentiment has swung from moderately bullish to clearly bearish. The third-quarter release, due before the open on October 30, is the first real test of whether the recovery narrative was a turning point or a false start.
Imperial Oil heads into its third-quarter report with a strange mix of strength and fragility. Commodity prices have handed the company a powerful earnings tailwind, yet the last call was defined by a genuine guidance cut: downstream throughput expectations were lowered about 6%, and full-year upstream production was steered toward the low end of its range. The question for the October 30 release, due before the open, is whether pricing can keep masking operational hiccups, or whether the stumbles management flagged in July bleed into the numbers.
Kite Realty Group Trust heads into its third-quarter report with an awkward disconnect. Management spent its last call describing a business that is getting better by almost every operating measure, raising same-property NOI guidance for the second straight quarter and touting its strongest balance sheet in years. The market responded by sending the shares down 17.6% since that report, a 22.6-point gap versus the S&P 500. Either investors see something the operating data does not yet show, or the stock is pricing in risks that the October 30 release, due before the open, could put to rest.
Kenvue heads into its third-quarter report with a gap between sales and profit that the company has not yet explained away. Wall Street expects revenue to rise at a low single-digit pace, yet earnings per share are projected to be exactly where they were a year ago. For a consumer health company built on mature, heavily advertised brands, that gap is the story. When the top line grows and the bottom line does not, something in the middle is absorbing the gains, and shareholders want to know whether that pressure is temporary or structural.
Lear raised its full-year outlook in July for the first time in a year of beat-and-hold quarters. Since then the stock has fallen 16% while the S&P 500 gained nearly 4%. That gap frames the third-quarter report due before the open on October 30. The market is pricing in something worse than management described. The results will show whether the summer raise was a turning point or the high-water mark before a tougher second half.
LyondellBasell heads into its third-quarter report with a question that matters more than the headline beat or miss: how much of last quarter's blowout was durable self-help, and how much was a temporary windfall from Middle East supply disruption? The company delivered $4.30 a share in the second quarter, its best showing in years. Wall Street now expects that number to fall by more than a third. Even after that cut, the Street is still looking for a sharp recovery from a year ago.
Three months ago Magna International delivered something it had held back for most of a year: a clean, multi-line guidance raise built on operational execution rather than vehicle volume. The market has since shrugged. Shares are down about 7% since that report while the S&P 500 gained nearly 4%, so the third-quarter release on October 30 arrives with a pointed question. Was the second quarter's margin step-up structural, as management argued, or did it mark a high-water mark for the year?
Mastech Digital heads into its third-quarter report with an awkward gap between what management is selling and what the income statement shows. Two consecutive strong quarters of Data and AI bookings have given executives a far more confident tone, yet consolidated revenue has fallen for several straight quarters and the stock has dropped almost 17% since the last report. This release is the first real chance to see whether those bookings are turning into revenue or are simply cushioning a shrinking legacy staffing base.